Cargando…
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
PURPOSE: To compare napabucasin (generator of reactive oxygen species) plus paclitaxel with paclitaxel only in patients with second-line advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. PATIENTS AND METHODS: In the double-blind, phase III BRIGHTER study (NCT02178956), patients wer...
Autores principales: | Shah, Manish A., Shitara, Kohei, Lordick, Florian, Bang, Yung-Jue, Tebbutt, Niall C., Metges, Jean-Phillippe, Muro, Kei, Lee, Keun-Wook, Shen, Lin, Tjulandin, Sergei, Hays, John L., Starling, Naureen, Xu, Rui-Hua, Sturtz, Keren, Fontaine, Marilyn, Oh, Cindy, Brooks, Emily M., Xu, Bo, Li, Wei, Li, Chiang J., Borodyansky, Laura, Van Cutsem, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433958/ https://www.ncbi.nlm.nih.gov/pubmed/35833783 http://dx.doi.org/10.1158/1078-0432.CCR-21-4021 |
Ejemplares similares
-
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
por: Tan, Lavinia, et al.
Publicado: (2023) -
Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
por: Shitara, Kohei, et al.
Publicado: (2023) -
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021) -
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022) -
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
por: Takahashi, Shunji, et al.
Publicado: (2021)